Drug intelligence / Profile preview

CPDA-1

Development stage: Unknown
Lead developer: Fenwal
Modality: Small Molecules
Administration: Intravenous

Overview

CPDA-1 (Citrate-phosphate-dextrose-adenine) is a sterile, non-pyrogenic intravenous solution used as an anticoagulant and preservative for the collection and storage of whole blood and red blood cells. It contains sodium citrate (as an anticoagulant), citric acid (buffering agent), monobasic sodium phosphate (buffering agent), dextrose (energy source for red blood cells), and adenine (to support ATP synthesis in stored erythrocytes). The addition of adenine extends the shelf life of stored whole blood from 21 to 35 days compared to earlier solutions. CPDA-1 is widely used in human and veterinary transfusion medicine to maintain red cell viability during storage[1][2][5].

Brand names: CPDA-1CPDA1CPDA 1
Other names: Citrate-phosphate-dextrose-adenineAnticoagulant citrate phosphate dextrose adenine solutionCPDA

Beyond the preview

Go deeper on CPDA-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPDA-1.

Explore the full profile